1. Home
  2. NMFC vs IMMX Comparison

NMFC vs IMMX Comparison

Compare NMFC & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Mountain Finance Corporation

NMFC

New Mountain Finance Corporation

HOLD

Current Price

$7.04

Market Cap

745.2M

Sector

Finance

ML Signal

HOLD

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$10.63

Market Cap

736.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMFC
IMMX
Founded
2010
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
745.2M
736.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NMFC
IMMX
Price
$7.04
$10.63
Analyst Decision
Hold
Strong Buy
Analyst Count
4
5
Target Price
$8.63
$19.20
AVG Volume (30 Days)
838.3K
2.3M
Earning Date
05-04-2026
05-08-2026
Dividend Yield
15.27%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.80
$1.94
52 Week High
$10.90
$12.14

Technical Indicators

Market Signals
Indicator
NMFC
IMMX
Relative Strength Index (RSI) 39.48 56.13
Support Level $6.80 $7.99
Resistance Level $7.31 $11.87
Average True Range (ATR) 0.18 0.86
MACD 0.02 0.05
Stochastic Oscillator 47.06 40.35

Price Performance

Historical Comparison
NMFC
IMMX

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: